ARK Investment Management LLC Increases Stock Position in Cellebrite DI Ltd. $CLBT

ARK Investment Management LLC increased its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT) by 55.1% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 133,518 shares of the company’s stock after purchasing an additional 47,455 shares during the quarter. ARK Investment Management LLC owned 0.06% of Cellebrite DI worth $2,474,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. Venturi Wealth Management LLC lifted its holdings in Cellebrite DI by 5.0% during the third quarter. Venturi Wealth Management LLC now owns 14,700 shares of the company’s stock valued at $272,000 after purchasing an additional 700 shares in the last quarter. CWM LLC grew its stake in Cellebrite DI by 85.7% during the 3rd quarter. CWM LLC now owns 1,560 shares of the company’s stock valued at $29,000 after acquiring an additional 720 shares in the last quarter. Blue Trust Inc. lifted its position in Cellebrite DI by 4.0% during the third quarter. Blue Trust Inc. now owns 23,121 shares of the company’s stock worth $428,000 after buying an additional 898 shares in the last quarter. SkyView Investment Advisors LLC boosted its holdings in Cellebrite DI by 2.6% in the 2nd quarter. SkyView Investment Advisors LLC now owns 37,708 shares of the company’s stock valued at $597,000 after purchasing an additional 970 shares during the last quarter. Finally, Fox Run Management L.L.C. grew its position in Cellebrite DI by 3.9% in the second quarter. Fox Run Management L.L.C. now owns 30,359 shares of the company’s stock worth $486,000 after acquiring an additional 1,127 shares during the period. 45.88% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have commented on CLBT. Lake Street Capital upped their price target on Cellebrite DI from $22.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cellebrite DI in a report on Monday, December 29th. Bank of America raised their price objective on shares of Cellebrite DI from $24.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, November 13th. JPMorgan Chase & Co. lifted their price objective on shares of Cellebrite DI from $23.00 to $24.00 and gave the stock an “overweight” rating in a research report on Thursday, November 13th. Finally, Needham & Company LLC decreased their target price on Cellebrite DI from $24.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, February 12th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $22.50.

Cellebrite DI Stock Performance

Shares of CLBT stock opened at $15.19 on Friday. The stock has a market cap of $3.79 billion, a PE ratio of 49.00, a P/E/G ratio of 2.17 and a beta of 1.30. The stock has a fifty day moving average price of $15.67 and a 200 day moving average price of $16.95. Cellebrite DI Ltd. has a 1 year low of $11.76 and a 1 year high of $20.86.

Cellebrite DI (NASDAQ:CLBT) last released its quarterly earnings results on Wednesday, February 11th. The company reported $0.14 EPS for the quarter, meeting the consensus estimate of $0.14. Cellebrite DI had a net margin of 16.47% and a return on equity of 20.43%. The business had revenue of $128.82 million for the quarter, compared to analyst estimates of $126.07 million. During the same period in the prior year, the business earned $0.10 earnings per share. The company’s quarterly revenue was up 28.8% on a year-over-year basis. As a group, equities research analysts predict that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.